Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia
Open Access
- 25 April 2018
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 284 (3) , 292-306
Abstract
Objective: Immunotherapy using vitamin D (vitD3) and phenylbutyrate (PBA) may support standard drug regimens used to treat infectious diseases. We investigated if vitD3 + PBA enhanced clinical recovery from pulmonary tuberculosis (TB).Methods: A randomized controlled trial was conducted in Addis Ababa, Ethiopia. Patients with smear‐positive or smear‐negative TB received daily oral supplementation with 5000 IU vitD3 and 2 × 500 mg PBA or placebo for 16 weeks, together with 6‐month chemotherapy. Primary end‐point: reduction of a clinical composite TB score at week 8 compared with baseline using modified intention‐to‐treat (mITT, n = 348) and per‐protocol (n = 296) analyses. Secondary end‐points: primary and modified TB scores (week 0, 4, 8, 16, 24), sputum conversion, radiological findings and plasma 25(OH)D3 concentrations.Results: Most subjects had low baseline plasma 25(OH)D3 levels that increased gradually in the vitD3 + PBA group compared with placebo (P < 0.0001) from week 0 to 16 (mean 34.7 vs. 127.4 nmol L−1). In the adjusted mITT analysis, the primary TB score was significantly reduced in the intervention group at week 8 (−0.52, 95% CI −0.93, −0.10; P = 0.015) while the modified TB score was reduced at week 8 (−0.58, 95% CI −1.02, −0.14; P = 0.01) and 16 (−0.34, 95% CI −0.64, −0.03; P = 0.03). VitD3 + PBA had no effect on longitudinal sputum‐smear conversion (P = 0.98). Clinical adverse events were more common in the placebo group (24.3%) compared with the vitD3 + PBA group (12.6%).Conclusion: Daily supplementation with vitD3 + PBA may ameliorate clinical TB symptoms and disease‐specific complications, while the intervention had no effect on bacterial clearance in sputum.Keywords
Funding Information
- National Institutes of Health (R25TW009337)
- Myndigheten för Samhällsskydd och Beredskap
- Styrelsen för Internationellt Utvecklingssamarbete (2010‐7938)
This publication has 41 references indexed in Scilit:
- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible TuberculosisClinical Infectious Diseases, 2016
- Oral intake of phenylbutyrate with or without vitamin D3upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosisBMC Pulmonary Medicine, 2013
- Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis’BMC Infectious Diseases, 2013
- Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it.2012
- Early treatment response evaluated by a clinical scoring system correlates with the prognosis of pulmonary tuberculosis patients in Ethiopia: A prospective follow-up studyScandinavian Journal of Infectious Diseases, 2012
- Vitamin D and the Immune System: New Perspectives on an Old ThemeRheumatic Disease Clinics of North America, 2012
- High Doses of Vitamin D to Reduce Exacerbations in Chronic Obstructive Pulmonary DiseaseAnnals of Internal Medicine, 2012
- Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2011
- Serum 25-hydroxy-vitamin D3 concentrations increase during tuberculosis treatment in Tanzania.2010
- Phenylbutyrate Induces Antimicrobial Peptide ExpressionAntimicrobial Agents and Chemotherapy, 2009